POCT, Immunofluorescent Platform, Bidirectional Lateral Flow Test Platform, Quality Control Products

  • Year Founded: 2001
  • Headquarters: Shenzhen,China
  • Estimated Employees: N/A
  • Product Lines:
    • Immunofluorescent Platform
    • Bidirectional Lateral Flow Test Platform
    • Diagnostic Test Kits
    • Quality Control Software
    • Quality Control Products
  • Products:
    • TZ-301 immunofluorescence detector
    • TZ-310/TZ-320 Automatic Immunofluorescence Detector
    • MINI/SSJ-2 Multifunctional Immunoassay Instrument
    • CK-MB/cTnI/Myoglobin/NT-proBNP/PCT/D-Dimer/ Quality Control
ReLIA TZ-301 immunofluorescence detector

TZ-301 immunofluorescence detector

ReLIA TZ-310 Automatic Immunofluorescence Detector

TZ-310 Automatic Immunofluorescence Detector

ReLIA SSJ-2 Multifunctional Immunoassay Instrument

SSJ-2 Multifunctional Immunoassay Instrument

ReLIA MINI Multifunctional Immunoassay Instrument

MINI Multifunctional Immunoassay Instrument

Troponin I/Myoglobin/Creatine Kinase Isozyme (cTnI/MYO/CK-MB) Joint Detection Kit

cTnI/MYO/CK-MB Joint Detection Kit

Since its foundation in 2001, ReLIA Biotech has been at the forefront of research in point of care testing technologies, with it’s primary research and development centre located in Silicon Valley, California. Currently, it holds its Asian Pacific headquarters at the Shekou Free Trade Zone, Shenzhen, as well as large scale production and R&D centers in Shenzhen and Jiangsu. These centers have passed both the CFDA and ISO-13485 audit certification.

Under the guidance of Dr. Willian J. Rutter, our company’s founder, ReLIA has adhered to a diligent attitude towards research. We mold modern developments into technological advancement/systems, which promote rapid diagnostic services and improve the health and wellbeing of patients whilst simultaneously reducing medical costs.

Currently, the company focuses on two categories of rapid detection systems: The multi-functional immunoassay system and immunofluorescence detection system. Both of these systems cover the detection of biomarkers for cardiovascular, acute kidney injury and inflammatory related conditions.